# A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

> **NCT04949503** · — · COMPLETED · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 1931 (actual)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** nimotuzumab

## Key facts

- **NCT ID:** NCT04949503
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-08
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-04-30
- **Target enrollment:** 1931 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949503, "A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04949503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*